DE69232815T2 - Lungentransfektion durch verabreichung von transgenen im aerosol - Google Patents

Lungentransfektion durch verabreichung von transgenen im aerosol

Info

Publication number
DE69232815T2
DE69232815T2 DE69232815T DE69232815T DE69232815T2 DE 69232815 T2 DE69232815 T2 DE 69232815T2 DE 69232815 T DE69232815 T DE 69232815T DE 69232815 T DE69232815 T DE 69232815T DE 69232815 T2 DE69232815 T2 DE 69232815T2
Authority
DE
Germany
Prior art keywords
transgenes
aerosol
administration
transfection
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232815T
Other languages
English (en)
Other versions
DE69232815D1 (de
Inventor
J Debs
Ning Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69232815D1 publication Critical patent/DE69232815D1/de
Application granted granted Critical
Publication of DE69232815T2 publication Critical patent/DE69232815T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
DE69232815T 1991-12-17 1992-12-17 Lungentransfektion durch verabreichung von transgenen im aerosol Expired - Fee Related DE69232815T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80929191A 1991-12-17 1991-12-17
US07/972,135 US5858784A (en) 1991-12-17 1992-11-05 Expression of cloned genes in the lung by aerosol- and liposome-based delivery
PCT/US1992/011008 WO1993012756A2 (en) 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery

Publications (2)

Publication Number Publication Date
DE69232815D1 DE69232815D1 (de) 2002-11-21
DE69232815T2 true DE69232815T2 (de) 2003-09-18

Family

ID=27123206

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232815T Expired - Fee Related DE69232815T2 (de) 1991-12-17 1992-12-17 Lungentransfektion durch verabreichung von transgenen im aerosol

Country Status (8)

Country Link
US (3) US5858784A (de)
EP (1) EP0619742B1 (de)
JP (2) JPH07505134A (de)
AU (1) AU679170B2 (de)
CA (1) CA2126103C (de)
DE (1) DE69232815T2 (de)
ES (1) ES2185624T3 (de)
WO (1) WO1993012756A2 (de)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US8153602B1 (en) * 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
AU3467193A (en) * 1991-12-17 1993-07-19 Regents Of The University Of California, The Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
WO1994005782A1 (en) * 1992-09-10 1994-03-17 Trustees Of Tufts College In vivo production of transgenic organ by introducing the transgene via lumen
EP1624068A1 (de) 1993-06-01 2006-02-08 Life Technologies Inc. Genetische Impfung mit kationischen Lipidstoffen
US5688677A (en) * 1993-10-13 1997-11-18 Genzyme Corporation Deoxyribonucleic acids containing inactivated hormone responsive elements
US6887856B1 (en) 1993-10-15 2005-05-03 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
WO1995010538A1 (en) * 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
FR2711523B1 (fr) 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6383814B1 (en) * 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
HU221204B1 (en) * 1994-12-24 2002-08-28 Univ Cambridge Tech Use of nucleic acid for production of pharmaceuticals with tranfecting effect of nucleic acid on female mammals reproductive tract
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU771241B2 (en) * 1995-06-07 2004-03-18 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU723163B2 (en) * 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU7078396A (en) * 1995-09-27 1997-04-30 Regents Of The University Of California, The Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
US5869715A (en) * 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
US6156567A (en) * 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
WO1998010796A1 (en) * 1996-09-12 1998-03-19 Genemedicine, Inc. Compositions and methods for pulmonary gene delivery
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
AU732447B2 (en) 1996-10-24 2001-04-26 Vanderbilt University Gene delivery and expression in areas inaccessible to direct protein delivery
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1007673B1 (de) 1997-07-30 2008-12-17 Emory University Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US20050142126A1 (en) * 1997-08-20 2005-06-30 Bernard Knoops Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
AU747438B2 (en) 1997-09-24 2002-05-16 Regents Of The University Of California, The Non-primate lentiviral vectors and packaging systems
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US6375980B1 (en) * 1998-01-08 2002-04-23 Research Development Foundation Stabilization of lipid:DNA formulations during nebulization
TW520294B (en) * 1998-01-08 2003-02-11 Res Dev Foundation Stabilization of lipid: DNA formulations during nebulization
US6410328B1 (en) * 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
WO1999039741A2 (en) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US6158431A (en) * 1998-02-13 2000-12-12 Tsi Incorporated Portable systems and methods for delivery of therapeutic material to the pulmonary system
US6221848B1 (en) 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
AU757894B2 (en) * 1998-05-21 2003-03-13 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
AU4007899A (en) * 1998-05-21 1999-12-06 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
CN1317009A (zh) * 1998-08-03 2001-10-10 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
ES2281199T3 (es) * 1998-11-12 2007-09-16 Transave, Inc. Sistema de inhalacion.
EP1839648A3 (de) * 1998-11-12 2007-11-21 Transave, Inc. Inhalationssystem
EP1129064B1 (de) 1998-11-12 2008-01-09 Invitrogen Corporation Transportreagentien
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000050062A2 (en) * 1999-02-24 2000-08-31 North Carolina State University Methods and compositions for altering mucus secretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
CN1330513A (zh) * 1999-04-06 2002-01-09 东卡罗来纳大学 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
JP4932086B2 (ja) * 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
WO2001021837A1 (en) * 1999-09-23 2001-03-29 The General Hospital Corporation Methods for potentiating antisense rna techniques
JP2003514855A (ja) 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
CA2382133C (en) * 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
DE60227157D1 (de) * 2001-02-13 2008-07-31 Us Gov Sec Army Impstoffe zur transkutanen immunisierung gegen reisediarrhö
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
AU2002256398A2 (en) * 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
CA2449054C (en) * 2001-05-30 2011-01-04 The Scripps Research Institute Integrin targeting liposome for nucleic acid delivery
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US6793912B2 (en) * 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
WO2003037302A1 (en) * 2001-10-30 2003-05-08 Windsor J Brian Method and system for the co-isolation of cognate dna, rna and protein sequences and method for screening co-isolates for defined activities
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US20040110295A1 (en) * 2002-05-28 2004-06-10 Maxygen, Inc., A Delaware Corporation Nucleic acid vectors
ES2354607T3 (es) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. Procedimiento y aparato para producir liposomas.
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
EP1545459A4 (de) * 2002-08-02 2007-08-22 Transave Inc Platinaggregate und verfahren zu ihrer herstellung
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
KR101301653B1 (ko) * 2002-10-29 2013-08-30 트랜세이브, 인코포레이티드 항감염제의 지속적인 방출
CN1708724A (zh) * 2002-11-01 2005-12-14 科比恩公司 多区域垂直排列液晶显示器
JP4838114B2 (ja) 2003-02-04 2011-12-14 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
DK1625149T3 (en) 2003-05-01 2016-05-30 Cornell Res Foundation Inc METHOD AND carrying complexes for delivery of molecules to cells
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
CN101291653B (zh) * 2003-07-16 2012-06-27 普洛体维生物治疗公司 脂质包封的干扰rna
US7291604B2 (en) 2003-09-03 2007-11-06 The General Hospital Corporation Methods of treating restenosis
CA2551022C (en) 2003-09-15 2013-06-04 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
DK1687066T3 (da) 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
KR20060123413A (ko) * 2003-12-03 2006-12-01 추가이 세이야쿠 가부시키가이샤 포유류 β 액틴 프로모터를 이용한 발현계
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
AU2005206053A1 (en) * 2004-01-23 2005-08-04 Keio University Support accumulating in injured part in vascular channel
CA2971928C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2005078848A2 (en) * 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
EP1755623A4 (de) * 2004-05-21 2007-10-17 Transave Inc Behandlung von lungenerkrankungen und zuständen vor einer lungenerkrankung
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
CA2569645C (en) 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
EP1811963A4 (de) * 2004-11-08 2010-01-06 Transave Inc Verfahren zur krebsbehandlung mit intraperitoneal verabreichten platinverbindungsformulierungen auf lipidbasis
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
EP1866414B9 (de) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20110178092A1 (en) * 2005-06-22 2011-07-21 Akbar Ali HIV-1 Protease Inhibitors
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
US7541340B2 (en) * 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
CA2627585A1 (en) * 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
EP3067047B1 (de) 2005-12-08 2022-04-20 Insmed Incorporated Antiinfektive zusammensetzungen auf lipidbasis zur behandlung von lungeninfekten
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
JP2009525757A (ja) 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１
KR100745833B1 (ko) 2006-03-06 2007-08-02 고려대학교 산학협력단 양이온성 골드 나노입자와 유전자의 복합체 조성물
US7846908B2 (en) * 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
US8968702B2 (en) * 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
WO2007124131A2 (en) * 2006-04-20 2007-11-01 The University Of North Carolina At Chapel Hill Hybrid nanomaterials as multimodal imaging contrast agents
CA2652770A1 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
BRPI0714953A2 (pt) 2006-07-26 2013-07-16 Biomarck Pharmaceuticals Ltd mÉtodos para atenuar a liberaÇço de mediadores inflamatàrios e peptÍdeos éteis nesse sentido
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
WO2008137717A1 (en) * 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2008144591A2 (en) 2007-05-16 2008-11-27 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
CN101939019B (zh) 2008-02-07 2014-07-16 康奈尔大学 用于预防或治疗胰岛素抵抗性的方法
US20110135571A1 (en) * 2008-02-22 2011-06-09 Wenbin Lin Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
EP3243521B1 (de) 2008-02-26 2020-05-27 Cornell University Peptide zur verwendung zur prävention oder behandlung von akutem nierenversagen
BRPI0911332A2 (pt) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc composições e uso de inibidores de epas1
CA2758415C (en) 2008-04-14 2019-06-04 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
EP2294184A4 (de) 2008-06-30 2013-03-06 Mesoblast Inc Behandlung von augenerkrankungen und exzessiver neovaskularisation mithilfe einer kombinierten therapie
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
EP2743265B1 (de) 2008-10-09 2017-03-15 Arbutus Biopharma Corporation Verbesserte Aminolipide und Verfahren zur Freisetzung von Nukleinsäuren
EP2361098B1 (de) 2008-10-31 2019-08-28 The General Hospital Corporation Zusammensetzungen und verfahren zur abgabe einer substanz an ein biologisches target
EP2344519B1 (de) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminale fragmente von glucagon-ähnlichem peptid-1 (glp-1)
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
WO2010120431A2 (en) 2009-03-20 2010-10-21 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods for the prevention and treatment of burn injuries and secondary complications
JP2010251707A (ja) * 2009-03-27 2010-11-04 Fujitsu Ltd 配線基板及び半導体装置
EP2756845B1 (de) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
JP5909182B2 (ja) 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
HRP20231277T1 (hr) 2009-08-24 2024-02-02 Stealth Biotherapeutics Inc. Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije
WO2011041385A2 (en) 2009-09-29 2011-04-07 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
EP3603658A1 (de) * 2009-10-05 2020-02-05 Cornell University Verfahren zur prävention oder behandlung von herzfibrose
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
CN103830719A (zh) 2009-12-31 2014-06-04 康肽德生物医药技术有限公司 用于进行冠状动脉旁路移植手术的方法
US20130195837A1 (en) 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CN102834408A (zh) 2010-01-25 2012-12-19 康奈尔大学 芳香族阳离子肽及其用途
WO2011106525A2 (en) 2010-02-26 2011-09-01 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
EP3040080A1 (de) 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Kombinationstherapien mit cyclosporin und aromatischen kationischen peptiden
US20130078238A1 (en) 2010-04-29 2013-03-28 Hadasit Medical Research Services & Decvelopment Co. Ltd. Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
WO2011139992A1 (en) 2010-05-03 2011-11-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN105879008A (zh) 2010-07-09 2016-08-24 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2012054718A2 (en) 2010-10-22 2012-04-26 The General Hospital Corporation Treating long qt syndrome
WO2012065182A2 (en) 2010-11-12 2012-05-18 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
EP2655409A4 (de) 2010-12-22 2015-07-01 Univ Leland Stanford Junior Superagonisten und antagonisten von interleukin-2
EP3108975A1 (de) 2011-03-24 2016-12-28 Cornell University Aromatische-kationische peptide und verwendungen davon
EP2691515A2 (de) 2011-03-31 2014-02-05 President and Fellows of Harvard College Einmalige population aus regulatorischen t-zellen zur regulierung von geweberegeneration und wundheilung
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
EP3494974B1 (de) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metall-bisphosphonat-nanopartikel zur krebstherapie sowie bildgebung und zur behandlung von knochenerkrankungen
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
GB201118704D0 (en) * 2011-10-28 2011-12-14 Univ Oxford Cystic fibrosis treatment
JP2014533953A (ja) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 治療用ｒｎａスイッチ組成物及び使用方法
CA2858550A1 (en) 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2865317A1 (en) 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
US10808008B2 (en) 2012-02-23 2020-10-20 Cornell University Aromatic-cationic peptides and uses of same
US9603897B2 (en) 2012-03-12 2017-03-28 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apolipoprotein D
US9534059B2 (en) 2012-04-13 2017-01-03 Children's Medical Center Corporation TIKI inhibitors
CN104349783B (zh) 2012-05-21 2018-07-13 英斯麦德公司 治疗肺部感染的系统
EP2858679B1 (de) * 2012-06-08 2021-02-24 Translate Bio, Inc. Pulmonale verabreichung von mrns an nicht pulmonale zielzellen
CA2880643A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
CN112451486A (zh) 2012-09-04 2021-03-09 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
EP2908839B1 (de) 2012-10-22 2019-08-21 Stealth Peptides International, Inc. Verfahren zur verringerung der gefahren im zusammenhang mit herzinsuffizienz und damit zusammenhängenden faktoren
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
RU2675859C2 (ru) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
EP3287172A1 (de) 2012-12-06 2018-02-28 Stealth Peptides International, Inc. Zusammenfassungen von peptidtherapeutischen wirkstoffen und verfahren zur verwendung davon
EP3789022A1 (de) 2012-12-27 2021-03-10 Massachusetts Eye & Ear Infirmary Behandlung von rhinosinusitis mit p-glycoprotein-hemmern
EP2943190B1 (de) 2013-01-11 2019-01-02 Massachusetts Eye & Ear Infirmary Cyp450-lipid-metaboliten zur unterdrückung von entzündungen und angiogenese
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP3673913A1 (de) 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Verbindungen zur behandlung von mitochondrialen erkrankungen
DK2961420T3 (da) 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
WO2014160221A1 (en) 2013-03-13 2014-10-02 The General Hospital Corporation Photoswitchable hdac inhibitors
WO2014159878A2 (en) 2013-03-13 2014-10-02 Regents Of The University Of California Intranasal administration of guanidinylated aminoglycosides
DK2970225T3 (en) 2013-03-14 2018-09-24 Onyx Therapeutics Inc DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
CA2904350A1 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Glycine, mitochondrial one-carbon metabolism, and cancer
CA2912386A1 (en) 2013-05-14 2014-11-20 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricular remodeling
US9737525B2 (en) 2013-06-07 2017-08-22 The General Hospital Corporation Small molecule activators of NRF2 pathway
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
CA2916486A1 (en) 2013-06-26 2015-01-22 Stealth Biotherapeutics Corp Methods and compositions comprising an aromatic peptide for regulating serca2a expression levels in myocardinal infarction
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2015034996A1 (en) 2013-09-06 2015-03-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
CA2932408A1 (en) 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
EP3134102B1 (de) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonisten, partielle agonisten und antagonisten von interleukin-2
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
EP3143166A4 (de) 2014-05-16 2018-04-18 University of Massachusetts Behandlung von chronischer myelogener leukämie (cml)
EP3501532A3 (de) 2014-05-28 2019-07-17 Stealth BioTherapeutics Corp Therapeutische zusammensetzungen mit frataxin, lactoferrin, sowie mitochondrialen energieerzeugungsenzymen und verwendungen davon
CA2950410A1 (en) 2014-05-28 2015-12-03 D. Travis Wilson Therapeutic compositions including therapeutic small molecules and uses thereof
EP3154694A1 (de) 2014-06-13 2017-04-19 Children's Medical Center Corporation Produkte und verfahren zur isolierung von mitochondrien
WO2015195737A1 (en) 2014-06-17 2015-12-23 Stealth Peptides International, Inc. Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
US10179775B2 (en) 2014-08-11 2019-01-15 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
CN107106637B (zh) 2014-08-21 2021-06-25 康德生物医疗技术公司 用于疾病预防和治疗的方法和组合物
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2016061256A1 (en) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
EP3218373B1 (de) 2014-11-10 2020-07-22 Evrys Bio, LLC Anti-hcmv-zusammensetzungen und -verfahren
WO2016077240A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
WO2016077382A2 (en) 2014-11-11 2016-05-19 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
WO2016100401A1 (en) 2014-12-15 2016-06-23 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
CA2973585A1 (en) 2015-01-12 2016-07-21 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2016164642A1 (en) 2015-04-08 2016-10-13 The United States Of America, As Represented By The Secretary Of Health And Human Services Viral gene therapy as treatment for cholesterol storage disease or disorder
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
WO2016193945A2 (en) 2015-06-05 2016-12-08 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
EP3347377B1 (de) 2015-09-09 2021-02-17 Novartis AG Thymus-stroma-lymphopoietin(tslp)-bindende antikörper und verfahren zur verwendung der antikörper
TN2018000076A1 (en) 2015-09-09 2019-07-08 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
WO2017059338A1 (en) 2015-10-02 2017-04-06 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
CA3010599A1 (en) 2016-01-06 2017-07-13 D. Travis Wilson Methods and compositions for the prevention and treatment of duchenne muscular dystrophy
WO2017123933A1 (en) 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
JP2019523217A (ja) 2016-05-19 2019-08-22 ステルス バイオセラピューティックス コープ ミトコンドリアミオパシーの予防および治療のための組成物および方法
WO2017201528A1 (en) 2016-05-20 2017-11-23 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
WO2017218355A1 (en) 2016-06-15 2017-12-21 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
HUE055417T2 (hu) 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
US20200054660A1 (en) 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10913779B2 (en) 2017-01-25 2021-02-09 Counterpoint Biomedica Llc Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
EP3641814A4 (de) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. Verwendungen und verfahren für il-2-superagonisten, agonisten und fusionen davon
CA3068010A1 (en) 2017-06-20 2018-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
WO2019006155A1 (en) 2017-06-28 2019-01-03 Children's Medical Center Corporation PROMOTION OF PULMONARY GROWTH
KR20200032722A (ko) 2017-07-27 2020-03-26 노파르티스 아게 부분절단효소 내성 trem2 변이체
BR102017016440A2 (pt) * 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
JP7364552B2 (ja) 2017-08-02 2023-10-18 ザ ユニバーシティ オブ シカゴ Ｘ線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート
US11458139B2 (en) 2017-08-08 2022-10-04 Memorial Sloan Kettering Cancer Center Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor
US20210128702A1 (en) 2017-08-11 2021-05-06 Dana-Farber Cancer Institute, Inc. Use of a botulinum toxin agent for treating plasma cell disorders
EP3668968A1 (de) 2017-08-14 2020-06-24 Sanford Burnham Prebys Medical Discovery Institute Regulatoren der kardiogenen mesodermbildung
EP3668878A1 (de) 2017-08-18 2020-06-24 Amgen Inc. Verbindungen zur hemmung des mcl-1-proteins
EP3676270A1 (de) 2017-08-29 2020-07-08 Amgen Inc. Makrocyclische verbindungen zur hemmung des mcl-1-proteins
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
EP3697783A4 (de) 2017-10-18 2023-04-26 Evrys Bio, LLC Antivirale zusammensetzungen mit breitem spektrum und verfahren
WO2019126041A1 (en) 2017-12-18 2019-06-27 The General Hospital Corporation Glycoengineering
AU2019210204A1 (en) 2018-01-18 2020-08-13 EndoProtech, Inc. Treating microvascular dysfunction
WO2019155387A1 (en) 2018-02-07 2019-08-15 St. Jude Children's Research Hospital Epigenetic histone regulation mediated by cxorf67
US11730774B2 (en) 2018-02-28 2023-08-22 The Johns Hopkins University Bacterial biofilms and cancer
WO2019173181A1 (en) 2018-03-05 2019-09-12 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN112424352A (zh) 2018-05-11 2021-02-26 阿尔法阿诺麦里克公司 包括7′-5′-α-异头双环糖核苷的寡核苷酸缀合物
CN112533918A (zh) 2018-06-13 2021-03-19 安菲斯塔治疗有限责任公司 用于靶向Rpn11的双功能分子
WO2019238816A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting uchl5
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
US20210230545A1 (en) 2018-07-09 2021-07-29 St. Jude Children's Research Hospital Use of il-12 to alter epigenetic effector programs in cd8 t cells
WO2020023806A1 (en) 2018-07-25 2020-01-30 The Johns Hopkins University Compositions and methods for generation of heart field-specific progenitor cells
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US11938135B2 (en) 2018-10-16 2024-03-26 The Johns Hopkins University Compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
US11931397B2 (en) 2018-12-06 2024-03-19 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of Sengers syndrome
US20220136051A1 (en) 2019-02-22 2022-05-05 St. Jude Children's Research Hospital Methods for identifying and improving t cell multipotency
WO2020176863A1 (en) 2019-02-28 2020-09-03 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors
CN113905724A (zh) 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
GB2598520A (en) 2019-05-28 2022-03-02 Univ Shanghai Tech Composition and methods to treat ectodermal dysplasia 2, Clouston type
JP2022542882A (ja) 2019-07-24 2022-10-07 ステルス バイオセラピューティクス インコーポレイテッド 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
WO2021067836A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Corp Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
CN115315273A (zh) 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine Inc Vorgespannte il2-muteins-verfahren und -zusammensetzungen
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4126836A1 (de) 2020-04-03 2023-02-08 Stealth BioTherapeutics Inc. Zusammensetzungen und verfahren zur prävention und/oder behandlung von mitochondrialer erkrankung, einschliesslich friedreich-ataxie
CA3173673A1 (en) 2020-04-23 2021-10-28 The Regents Of The University Of California Genetically engineered phagocytes, and related compositions, vectors, methods and systems
US20230227555A1 (en) 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
CN116322754A (zh) 2020-08-05 2023-06-23 辛德凯因股份有限公司 Il10ra结合分子及使用方法
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
IL300736A (en) 2020-08-31 2023-04-01 Kezar Life Sciences Protein secretion inhibitors
MX2023005201A (es) 2020-11-04 2023-06-28 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
EP4251170A1 (de) 2020-11-25 2023-10-04 Akagera Medicines, Inc. Lipidnanopartikel zur abgabe von nukleinsäuren und zugehörige verfahren zur verwendung
EP4291306A1 (de) 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Menschliche monoklonale antikörper gegen pneumokokken-antigene
WO2023064942A1 (en) 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation
WO2023069255A1 (en) 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023101963A2 (en) 2021-11-30 2023-06-08 Northwestern University Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
WO2023133321A1 (en) 2022-01-10 2023-07-13 Stealth Biotherapeutics Inc. Small molecule peptidomimetic for the treatment of tauopathies
WO2023164250A1 (en) 2022-02-28 2023-08-31 Kezar Life Sciences Sec61 inhibitors and use thereof
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
GB202214445D0 (en) * 2022-09-30 2022-11-16 Imp College Innovations Ltd Gene therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354126A (en) * 1929-10-29 1931-08-06 Lucas Haendel Method and device for the production of cigarettes with tobacco coverings
US3826255A (en) * 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) * 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4268460A (en) * 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
DE3365744D1 (en) * 1982-01-22 1986-10-09 Fisons Plc Liposome and sodium cromoglycate compositions, and methods for their preparation
US4510929A (en) * 1982-04-30 1985-04-16 Bordoni Maurice E Disposable radioactive aerosol inhalation apparatus
US4649911A (en) * 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3545126A1 (de) * 1985-12-19 1987-06-25 Boehringer Mannheim Gmbh Verfahren zur verbesserung der expression von eukaryontenprotein
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
EP0281246A3 (de) * 1987-02-04 1989-07-12 Invitron Corporation Verfahren zur Erhöhung der Amplifikation und Expression fremder Gene
US5075229A (en) * 1987-06-16 1991-12-24 Ohio University Edison Animal Biotechnology Center Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase
WO1989002469A2 (en) * 1987-09-17 1989-03-23 Massachusetts Institute Of Technology Human erythroid-specific transcriptional enhancer
IL90514A (en) * 1988-06-03 1995-10-31 Us Health A fusion gene that contains a gene for multidrug resistance that is fused to a gene for adenine diamines
US4923949A (en) * 1988-08-03 1990-05-08 Kanegafuchi Chemical Industry Co., Ltd. Ethynylene-disilanylene copolymers and method of preparing same
EP0456640A1 (de) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
JPH04503957A (ja) * 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
DE69032284T2 (de) * 1989-03-21 1998-10-08 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
GB8909218D0 (en) * 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5240842A (en) * 1989-07-11 1993-08-31 Biotechnology Research And Development Corporation Aerosol beam microinjector
ES2210224T3 (es) * 1989-08-22 2004-07-01 Hsc Research Development Corporation Gen de la fibrosis quistica.
GB9020632D0 (en) * 1990-09-21 1990-10-31 Hsc Res Dev Corp Stable propagation of modified full length cystic fibrosis transmembrane conductance regulator protein cdna in heterologous systems
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0452457B1 (de) * 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
CA2037478A1 (en) * 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ES2078521T3 (es) * 1990-05-18 1995-12-16 Boehringer Ingelheim Int Nuevos conjugados de proteina-polication.
IT1246763B (it) 1990-07-11 1994-11-26 Frattini Costr Mecc Procedimento di trafilatura a caldo, specie su corpi estrusi od imbutiti ottenuti in alluminio ed apparecchiatura per l'attuazione delprocedimento
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
JPH06510036A (ja) * 1991-08-16 1994-11-10 バイカル・インコーポレイテッド 嚢胞性線維症の治療のための組成物および方法
WO1993004701A1 (en) * 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
AU3467193A (en) * 1991-12-17 1993-07-19 Regents Of The University Of California, The Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy

Also Published As

Publication number Publication date
WO1993012756A2 (en) 1993-07-08
US5641662A (en) 1997-06-24
JP2002003383A (ja) 2002-01-09
JPH07505134A (ja) 1995-06-08
US6468798B1 (en) 2002-10-22
AU3329193A (en) 1993-07-28
WO1993012756A3 (en) 1994-09-01
EP0619742B1 (de) 2002-10-16
DE69232815D1 (de) 2002-11-21
AU679170B2 (en) 1997-06-26
EP0619742A4 (en) 1997-06-04
CA2126103C (en) 2002-12-03
ES2185624T3 (es) 2003-05-01
US5858784A (en) 1999-01-12
EP0619742A1 (de) 1994-10-19
CA2126103A1 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
DE69232815T2 (de) Lungentransfektion durch verabreichung von transgenen im aerosol
NO921110D0 (no) Inhalator
DE69226921D1 (de) System zur Beendigung von durch einen Herzschrittmacher induzierten Tachykardien bei frequenzadaptierender Reizung
DE69133314D1 (de) Aerosolzubereitungen zur dosierten Abgabe
ATE421315T1 (de) Aerosolzubereitungen
AU3995189A (en) Swimming pool cleaner
DK619688D0 (da) Resuscitator til engangsbrug
DK479189D0 (da) Inhalator
DE69217483T2 (de) Abgabegerät von alkoholfreien getränken
IT1096151B (it) Respiratore artificiale automatico,in particolare per sale di rianimazione e per anestesia
DK168190D0 (da) Interferonpraeparat til nasal anvendelse
ITMI922721A0 (it) Composizioni farmaceutiche contenenti acido ursodesossicolico
NO891653L (no) Aminosyreestere og deres fremstilling.
DK564786A (da) 4-alkoxy-2-oxo-pyrrolidin-1-yl-eddikesyrealkylestere samt deres fremstilling og anvendelse
DK220389A (da) Synergistiske kombinationspraeparater og deres anvendelse som terapeutika
DK569587D0 (da) Lugtstofkomposition og dispenser herfor
IT8530725V0 (it) Elemento modulare componibile particolarmente per l'allestimento di controsoffittature, piani divisori e pareti non strutturali in genere.
IT8048667A0 (it) Struttura modulare in legno per giochi all'aperto
KR890021386U (ko) 초음파 가습기 노즐
IT1195378B (it) Perfezionamenti relativi a casseforme componibili,construttura modulare,per l'impiego dei tradizionali pannelli in legno da armature
AU531936B3 (en) Improvements in swimming pool construction
DK452084A (da) 7beta-acylamido-3-cephem-4-carboxylsyreestere samt deres fremstilling og anvendelse
IT8321884V0 (it) Interruttore bipolare o unipolare di tipo modulare e componibile.
IT8102505A0 (it) Cassaforma componibile, con struttura modulare per l'impiego dei tradizionali pannelli in legno per armature.
BR7101399U (pt) Disposicao introduzida em entretenimento voador

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee